Visiopharm (private company)

See something wrong or missing? Let us know
Offices:
Hørsholm
Business model:
B2B SAAS
Key People:
Michael Grunkin
Investors:
we tracked 4 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 2 transactions

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

M&A and Exit deals (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, research institutes, and hospitals all over the world.

Recently, Visiopharm has expanded to include ONCOtopix™ Dx a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and Virtual Double Staining. Their software is featured in over 800 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and a wide variety of microscopes and cameras.

Visiopharm, a privately owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis.

Companies with similar profile to Visiopharm:

CompanyCriteria
Denmark Area9 Lyceum
45%
  • Similar business models: B2B, SAAS
  • At least one vc investor: VF Venture (Vækstfonden)
  • Total raised in a similar range: 10M+ USD
Denmark Blackwood Seven
45%
  • Similar business models: B2B, SAAS
  • At least one vc investor: VF Venture (Vækstfonden)
  • Total raised in a similar range: 10M+ USD
Finland Glucostratus (Mendor)
44%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
  • Total raised in a similar range: 10M+ USD
Finland Blueprint Genetics
44%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
  • Total raised in a similar range: 10M+ USD
Finland BC Platforms
44%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
  • Total raised in a similar range: 10M+ USD
Denmark First Agenda
35%
  • Similar business models: B2B, SAAS
  • At least one vc investor: VF Venture (Vækstfonden)
Denmark Sekoia
35%
  • Similar verticals: Health services
  • Similar business models: SAAS
  • At least one vc investor: Northcap
Denmark Absolute Liquid Solutions
35%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: VF Venture (Vækstfonden)
Denmark CathVision
35%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: VF Venture (Vækstfonden)
Denmark QVEST
35%
  • Similar business models: B2B, SAAS
  • At least one vc investor: VF Venture (Vækstfonden)
Sweden Encare
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Norway iQey
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Finland Klinik
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Sweden Vint
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Norway Exonor
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Sweden Frisq
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Finland Fastroi
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Norway Be Your Best
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Norway CSAM
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS
Sweden Byon8
34%
  • Similar verticals: Health services
  • Similar business models: B2B, SAAS